Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study.

IF 12.2 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2026-08-11 DOI:10.1158/2643-3230.BCD-26-0128

Ruixian Xing, Apeng Yang, Juan Huang, Liang Wang, Wei Guo, Qu Cui, Xiaoqiong Tang, Yuanyuan Ma, Kai Hu, Tianheng He, Danyang Wu, Xiaofang Deng, Yajing Zhang, Kaili Zhong, Yang Liu, Yixian Guo, Ying Wang, Chan Long, Chongyang Wu, Xin Lu, Fengmin Li, Jiefei Bai, Jun Qian, Xuefei Sun, Wenrong Huang, Hui Zhou, Huilai Zhang, Ou Bai, Xiaobing Huang, Zhiyong Zeng, Lin Fu

{"title":"Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study.","authors":"Ruixian Xing, Apeng Yang, Juan Huang, Liang Wang, Wei Guo, Qu Cui, Xiaoqiong Tang, Yuanyuan Ma, Kai Hu, Tianheng He, Danyang Wu, Xiaofang Deng, Yajing Zhang, Kaili Zhong, Yang Liu, Yixian Guo, Ying Wang, Chan Long, Chongyang Wu, Xin Lu, Fengmin Li, Jiefei Bai, Jun Qian, Xuefei Sun, Wenrong Huang, Hui Zhou, Huilai Zhang, Ou Bai, Xiaobing Huang, Zhiyong Zeng, Lin Fu","doi":"10.1158/2643-3230.BCD-26-0128","DOIUrl":null,"url":null,"abstract":"<p><p>Relapsed or refractory CNS lymphoma (R/R CNSL) has limited treatment options. This multicenter retrospective study enrolled 84 consecutive R/R CNSL patients (median age 59 years; 53 PCNSL, 31 SCNSL) to evaluate efficacy and safety profiles of glofitamab therapy. With a median of 2.5 prior lines of therapy, the objective response rates (ORR) and complete response rates (CRR) for PCNSL were 88% (CRR 59%) with glofitamab monotherapy (n=32) and 100% (CRR 81%) with combination therapy (n=21), respectively; for SCNSL, ORR and CRR were 88% (CRR 75%) with glofitamab monotherapy (n=8) and 91% (CRR 65%) with combination therapy (n=23). At 14.7 months follow-up, median progression-free survival was 19.5 months for PCNSL and 13.5 months for SCNSL. Cytokine release syndrome occurred in 40% (all grade 1-2) of patients, and ICANS in 8%. Glofitamab-based therapy demonstrated substantial activity with manageable toxicity in this study, offering a promising treatment paradigm for R/R CNSL patients.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":12.2000,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2643-3230.BCD-26-0128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Relapsed or refractory CNS lymphoma (R/R CNSL) has limited treatment options. This multicenter retrospective study enrolled 84 consecutive R/R CNSL patients (median age 59 years; 53 PCNSL, 31 SCNSL) to evaluate efficacy and safety profiles of glofitamab therapy. With a median of 2.5 prior lines of therapy, the objective response rates (ORR) and complete response rates (CRR) for PCNSL were 88% (CRR 59%) with glofitamab monotherapy (n=32) and 100% (CRR 81%) with combination therapy (n=21), respectively; for SCNSL, ORR and CRR were 88% (CRR 75%) with glofitamab monotherapy (n=8) and 91% (CRR 65%) with combination therapy (n=23). At 14.7 months follow-up, median progression-free survival was 19.5 months for PCNSL and 13.5 months for SCNSL. Cytokine release syndrome occurred in 40% (all grade 1-2) of patients, and ICANS in 8%. Glofitamab-based therapy demonstrated substantial activity with manageable toxicity in this study, offering a promising treatment paradigm for R/R CNSL patients.

查看原文本刊更多论文

格非他单抗治疗复发或难治性中枢神经系统淋巴瘤：一项多中心回顾性研究

复发或难治性中枢神经系统淋巴瘤（R/R CNSL）的治疗选择有限。这项多中心回顾性研究纳入了84例连续的R/R CNSL患者（中位年龄59岁；53例PCNSL， 31例SCNSL），以评估格非他单抗治疗的疗效和安全性。在既往治疗中位数为2.5线的情况下，格非他单药治疗（n=32）的PCNSL客观缓解率（ORR）和完全缓解率（CRR）分别为88% （CRR 59%）和100% (CRR 81%)，联合治疗（n=21）；对于SCNSL，格非他单药治疗（n=8）的ORR和CRR分别为88% （CRR 75%）和91% (CRR 65%)，联合治疗（n=23）。在14.7个月的随访中，PCNSL的中位无进展生存期为19.5个月，SCNSL的中位无进展生存期为13.5个月。细胞因子释放综合征发生在40%（所有1-2级）的患者中，ICANS发生在8%。在这项研究中，以格洛非他单为基础的治疗显示出实质性的活性和可控的毒性，为R/R CNSL患者提供了一种有希望的治疗范例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.